Press release
Ocular Melanoma Market Analysis: Rising Prevalence, Breakthrough Therapies & Market Trends Through 2034 | DelveInsight
Ocular Melanoma - Market Insight, Epidemiology And Market Forecast - 2034
DelveInsight's latest report, "Ocular Melanoma - Market Insight, Epidemiology And Market Forecast - 2034 [https://www.delveinsight.com/report-store/ocular-melanoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]", combines robust epidemiological data with ocular melanoma market trends, competitive landscape analysis, and patient journey assessments in the 7MM which includes the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The report predicts that the ocular melanoma market is expected to grow positively in 7MM from approximately USD 340 million in 2023 during the forecast period (2024-2034). The US leads the market among 7MM, with a 60% market share in 2023, followed by the United Kingdom. Among the EU4 countries and the UK, the UK has the largest market size for ocular melanoma, while Spain holds the smallest share.
Download the Ocular Melanoma Market report to understand which factors are driving the Ocular Melanoma therapeutic market @ Ocular Melanoma Market Trends [https://www.delveinsight.com/sample-request/ocular-melanoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The report also analyzes historical and projected ocular melanoma epidemiology, segmented by ocular melanoma diagnosed incident cases, region-specific ocular melanoma cases, type-specific ocular melanoma cases, mutation-specific ocular melanoma cases, age-specific ocular melanoma cases, stage-specific ocular melanoma cases, and total treated cases of ocular melanoma.
The ocular melanoma patient pool is significant in the 7MM, with the US accounting for the highest number of diagnosed incident cases. Ocular melanoma primarily affects individuals aged 40-70, with a higher incidence in fair-skinned individuals and those with lighter eye colors. Other risk factors include dysplastic nevus syndrome, certain cutaneous nevi, and a family history of systemic and ocular cancers.
Ocular melanoma can be divided into uveal and non-uveal melanoma. Uveal melanoma comprises the larger group of ocular melanoma, with approximately 95% of all ocular melanoma cases, and includes choroidal, ciliary body, and iris melanoma. Non-uveal melanoma consists of conjunctival melanoma and other ocular melanomas originating from different sites.
Discover evolving trends in the Ocular Melanoma patient pool forecasts @ Ocular Melanoma Epidemiology Analysis [https://www.delveinsight.com/sample-request/ocular-melanoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The ocular melanoma market report also offers insights into current ocular melanoma treatment practices, emerging drugs, market share of individual therapies, and forecasts for the 7MM ocular melanoma market size from 2020 to 2034. Several innovative therapies have been approved by the FDA for treating ocular melanoma. KIMMTRAK (Immunocore) is a groundbreaking immunotherapy and the first FDA-approved metastatic uveal melanoma drug. Another significant therapy is HEPZATO KIT (Delcath Systems), a targeted hepatic artery infusion chemotherapy that delivers high doses of melphalan directly to the liver, where metastatic uveal melanoma often spreads, thus minimizing systemic side effects.
Additionally, immune checkpoint inhibitors such as YERVOY (BMS), which targets CTLA-4, and OPDIVO (BMS) or KEYTRUDA (Merck), which target PD-1, have been used off-label or in clinical trials for metastatic uveal melanoma; however, their efficacy in this type of melanoma is limited compared to their effectiveness in cutaneous melanoma.
DelveInsight's analysis indicates that the ocular melanoma clinical trials market is very active, with many investigational therapies at various development stages. Notable candidates include TBio-4101 (Turnstone Biologics), LNS8801 (Linnaeus Therapeutics), IOA-244 (iOnctura), SD-101 (TriSalus Life Sciences), and BVD-523 (Dana-Farber Cancer Institut/BioMed Valley Discoveries), among others. These emerging therapies represent significant advancements in the ocular melanoma treatment landscape, providing hope for improved survival rates and quality of life for patients with limited options.
Recently, in March 2025, IDEAYA Biosciences (NASDAQ: IDYA) received FDA Breakthrough Therapy Designation for darovasertib, a novel PKC inhibitor, as a neoadjuvant treatment for uveal melanoma. This designation was granted based on phase II trial data showing significant tumor shrinkage, eye preservation, and a manageable safety profile with low rates of severe adverse events.
In January 2025, the FDA awarded orphan drug status to an aptamer drug conjugate (ApDC) treatment developed by researchers in China. This gene-based therapy precisely delivers anti-tumor drugs to cancer cells, making it safer and more effective than traditional methods such as surgery and radiotherapy. These developments signal promising progress in the ocular melanoma clinical trials market.
Unlock which Ocular Melanoma emerging drug is expected to capture the largest market share in 7MM by 2034. Visit the Ocular Melanoma Drug Insights [https://www.delveinsight.com/sample-request/ocular-melanoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The comprehensive analysis of the ocular melanoma market indicates promising growth prospects through 2034, supported by advancements in diagnostics and therapeutics, increasing prevalence of the disease, and rising healthcare investments globally. Stakeholders across the pharmaceutical industry, healthcare providers, and investors can leverage these insights to navigate the evolving landscape effectively and contribute to improved patient outcomes in ocular melanoma management.
Table of Contents
1.
Key Insights
2.
Report Introduction
3.
Executive Summary of Ocular Melanoma
4.
Ocular Melanoma Market Overview at a Glance
5.
Key Events
6.
Ocular Melanoma Epidemiology and Market Forecast Methodology
7.
Ocular Melanoma: Disease Background and Overview
8.
Ocular Melanoma Treatment
9.
Ocular Melanoma Epidemiology and Patient Population
10.
Ocular Melanoma Patient Journey
11.
Ocular Melanoma Marketed Therapies
12.
Emerging Ocular Melanoma Drugs
13.
Key Cross
14.
Ocular Melanoma: Market Analysis
15.
Ocular Melanoma Unmet Needs
16.
SWOT Analysis
17.
KOL Views
18.
Market Access and Reimbursement
19.
Appendix
20.
DelveInsight Capabilities
21.
Disclaimer
22.
About DelveInsight
Related Reports
Melanoma Pipeline Insight [https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Melanoma Pipeline Insight provides comprehensive insights about the melanoma pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the melanoma companies, including IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed, AiVita Biomedical, Cytovation AS, Ono Pharmaceuticals, Neon Therapeutics, and Iovance Biotherapeutics, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ocular-melanoma-market-analysis-rising-prevalence-breakthrough-therapies-market-trends-through-2034-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ocular Melanoma Market Analysis: Rising Prevalence, Breakthrough Therapies & Market Trends Through 2034 | DelveInsight here
News-ID: 4160590 • Views: …
More Releases from ABNewswire
Diffuse Midline Glioma Treatment Landscape: FDA Approves MODEYSO, First Targeted …
DelveInsight Business Research's latest report highlights the transformative impact of the FDA's accelerated approval of MODEYSO (dordaviprone) by Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ). This landmark approval on August 6, 2025, marks the first targeted therapy specifically approved for diffuse midline glioma with H3 K27M mutations, offering new hope for pediatric and young adult patients suffering from this rare, aggressive, and historically fatal brain tumor with limited treatment options.
Key Diffuse Midline…
CAR-T Cell Therapy Landscape: Kite Pharma Acquires Interius BioTherapeutics for …
DelveInsight's latest analysis highlights the strategic significance of Gilead Sciences' subsidiary Kite Pharma's acquisition of Interius BioTherapeutics for $350 million, announced in August 2025. This landmark transaction reinforces Kite's leadership position in the CAR-T cell therapy market and expands its technological capabilities into next-generation allogeneic natural killer cell platforms, offering enhanced scalability and broader patient accessibility for cancer immunotherapy.
Key CAR-T Cell Therapy Market Highlights
*
Kite's acquisition of Interius strengthens its…
Small Cell Lung Cancer Market to Witness Breakthrough Transformation as Daiichi …
Daiichi Sankyo and Merck are pioneering a revolutionary approach in SCLC treatment with ifinatamab deruxtecan (I-DXd), which has secured Breakthrough Therapy Designation from the FDA for adult patients with extensive-stage small cell lung cancer experiencing disease progression following platinum-based chemotherapy. This landmark designation represents the first BTD for ifinatamab deruxtecan and marks a significant milestone in the collaborative efforts between these pharmaceutical giants.
Ifinatamab Deruxtecan: A Groundbreaking ADC Targeting B7-H3
Ifinatamab deruxtecan…
Dreamland Plumbing Highlights the Role of Probate Planning in Plumbing and Home …
Homeowners often think about plumbing as a routine concern. Leaks, clogs, and repairs are usually seen as minor issues that can be resolved quickly by calling a plumber. However, when a homeowner passes away or faces legal challenges related to their estate, these seemingly small problems can have bigger implications. Property maintenance, including plumbing, can influence estate value and the ease of probate proceedings.
Unattended plumbing issues can create complications for…
More Releases for Ocular
How the Ocular Pain Market Is Growing in 2025 | What's New Treatments Are Coming …
According to the IMARC Group, the ocular pain market is expected to exhibit a CAGR of 7.66% during 2025-2035. This can be attributed to the growing use of services in teleophthalmology, which facilitates remote consultations and enhances patient adherence.
Ocular pain is the discomfort or distress experienced within or around the eye. The ocular pain market is experiencing significant growth driven by multiple factors. Primarily, the increasing prevalence of conditions such…
Key Influencer in the Ocular Implants Market 2025: Growing Geriatric Population …
What market dynamics are playing a key role in accelerating the growth of the ocular implants market?
The growth of the ocular implants market is foreseen to be driven by the global increase in the geriatric population. The term 'geriatric population' is specifically used to refer to individuals aged 65 years or above. Ocular implants offer a solution to age-specific eye ailments prevalent among the elderly, such as cataracts, glaucoma, and…
Neuropathic Ocular Pain Market Is Booming Worldwide 2025-2032 | OKYO Pharma, Lim …
Latest Report, titled "Neuropathic Ocular Pain Market" Trends, Share, Size, Growth, Opportunity and Forecast 2025-2032, by Coherent Market Insights offers a comprehensive analysis of the industry, which comprises insights on the market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.
The report features a comprehensive table of contents, figures, tables, and charts, as well as insightful analysis. The Neuropathic Ocular Pain market has been…
Neuropathic Ocular Pain Market Detailed In New Research Report 2024 |OKYO Pharma …
A recent report from Coherent Market Insight titled "Neuropathic Ocular Pain Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2031" presents a thorough examination of the industry landscape, offering insights into market analysis and trends. Alongside competitor and regional analysis, the report delves into contemporary advancements within the market.
Global Neuropathic Ocular Pain market is estimated to be valued at US$ 197.1 million in 2023 and is expected to…
Ocular Neuropathic Pain Market to witness Robust Expansion by 2031 - OKYO Pharma …
Ocular neuropathic pain (ONP) is chronic eye pain caused by nerve damage or dysfunction. It can result from various conditions, such as corneal nerve injury, ocular surgeries, infections, or systemic diseases like diabetes. Patients experience persistent, burning, or stabbing eye pain, often without visible signs of inflammation. Diagnosis involves detailed patient history, clinical examination, and sometimes specialized tests. Treatment focuses on managing pain and may include topical or systemic medications,…
Ocular Implant Market - Redefining Ophthalmic Solutions: Choose Ocular Implants …
Newark, New Castle, USA: The "Ocular Implant Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Ocular Implant Market: https://www.growthplusreports.com/report/ocular-implant-market/7864
This latest report researches the industry structure, sales, revenue,…
